Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, with Rapid Improvement Following IL-17A/IL-17F Blockade by Bimekizumab. J of Skin. 2024;8(6):1987-1992. doi:10.25251/skin.8.6.13